VAS-101 for Sickle Cell Disease

This trial tests a new gel called VAS-101, which contains curcumin, a compound from turmeric, to improve red blood cells in people with sickle cell disease (SCD). Researchers aim to determine if applying the gel to the skin enhances curcumin absorption compared to oral intake. People with stable sickle cell disease who haven't received a blood transfusion in the last two months may qualify for this study. Participants will visit the clinic for about 14 weeks, where the gel will be applied to their skin. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.

You may need to stop taking any products or supplements containing turmeric or curcumin during the study. If you are on medications like hydroxyurea, L-glutamine, or crizanlizumab, you must have been on a stable dose for at least 90 days before joining the trial.

Research shows that VAS-101, a skin gel containing curcumin from turmeric, is under testing for safety in people with sickle cell disease. Curcumin has improved red blood cell health, but the body struggles to absorb it when taken orally. VAS-101 addresses this issue by using a gel form.

Current studies focus on how well people tolerate VAS-101. Although specific safety data is not yet available, this phase 1 study aims to assess the safety and tolerability of VAS-101. Participants are closely monitored for any side effects during this phase.

The FDA has granted VAS-101 Orphan Drug Designation for sickle cell disease. This special status is given to treatments that show promise for rare diseases. While it doesn't guarantee safety, it indicates confidence in the treatment's potential benefits.

Researchers are excited about VAS-101 for sickle cell disease because it introduces Curcugen, a novel formulation of curcumin, as its active ingredient. Unlike traditional treatments like hydroxyurea and blood transfusions, which focus on managing symptoms and complications, VAS-101 may offer a new mechanism by targeting inflammation and oxidative stress directly associated with sickle cell pathophysiology. The potential for Curcugen to deliver targeted therapeutic benefits with possibly fewer side effects is generating interest in the scientific community.

Research has shown that curcumin, a substance found in turmeric, can improve the health of red blood cells in people with sickle cell disease (SCD). However, the body does not easily absorb curcumin when taken orally. VAS-101, which participants in this trial will receive, is a gel designed to enhance curcumin absorption through the skin. In studies with mice that have sickle cell disease, this gel showed promise in improving heart function and reducing pain and swelling. Early results also suggest it may help stabilize red blood cells and improve blood flow. These findings support VAS-101 as a potential treatment for SCD.²⁴⁶⁷⁸